These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16344254)

  • 1. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?
    Papagikos MA; Deguzman AF; Rossi PJ; McCullough DL; Clark PE; Lee WR
    Brachytherapy; 2005; 4(4):252-8. PubMed ID: 16344254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetry and cancer control after low-dose-rate prostate brachytherapy.
    Robert Lee W; Deguzman AF; McMullen KP; McCullough DL
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):52-9. PubMed ID: 15629593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone.
    Papagikos MA; Rossi PJ; Urbanic JJ; deGuzman AF; McCullough DL; Clark PE; Lee WR
    Am J Clin Oncol; 2007 Apr; 30(2):199-204. PubMed ID: 17414471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone.
    Rossi PJ; Urbanic J; Clark PE; McCullough DL; Lee WR
    Brachytherapy; 2008; 7(4):286-9. PubMed ID: 18928924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer.
    Rossi PJ; Clark PE; Papagikos MA; McCullough DL; Lee WR
    Urology; 2006 Feb; 67(2):349-53. PubMed ID: 16461084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer control after low-dose-rate prostate brachytherapy performed by a multidisciplinary team with no previous prostate brachytherapy experience.
    McMullen KP; deGuzman AF; McCullough DL; Lee WR
    Urology; 2004 Jun; 63(6):1128-31. PubMed ID: 15183965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equivalent uniform dose, D(90), and V(100) correlation with biochemical control after low-dose-rate prostate brachytherapy for clinically low-risk prostate cancer.
    Miles EF; Nelson JW; Alkaissi AK; Das S; Clough RW; Anscher MS; Oleson JR
    Brachytherapy; 2008; 7(2):206-11. PubMed ID: 18359669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
    Miles EF; Nelson JW; Alkaissi AK; Das S; Clough RW; Broadwater G; Anscher MS; Chino JP; Oleson JR
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):139-46. PubMed ID: 19836161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer.
    Burri RJ; Ho AY; Forsythe K; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1315-21. PubMed ID: 20044216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer.
    Morris WJ; Keyes M; Palma D; McKenzie M; Spadinger I; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Lapointe V; Berthelet E; Pai H; Harrison R; Kwa W; Bucci J; Racz V; Woods R
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1432-8. PubMed ID: 19036530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetric predictors of biochemical control of prostate cancer in patients randomised to external beam radiotherapy with a boost of high dose rate brachytherapy.
    Hoskin PJ; Rojas AM; Ostler PJ; Hughes R; Bryant L; Lowe GJ
    Radiother Oncol; 2014 Jan; 110(1):110-3. PubMed ID: 24100150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional dose metrics as predictors of biochemical failure and local recurrence after low-dose-rate prostate brachytherapy.
    Spadinger I; Chu J; Afsari Golshan M; Keyes M; Pickles T; Hamm J; Morris WJ
    Brachytherapy; 2015; 14(3):350-8. PubMed ID: 25638507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: The Memorial Sloan-Kettering Cancer Center experience.
    Zelefsky MJ; Chou JF; Pei X; Yamada Y; Kollmeier M; Cox B; Zhang Z; Schechter M; Cohen GN; Zaider M
    Brachytherapy; 2012; 11(4):245-9. PubMed ID: 21925957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution.
    Lee WR; deGuzman AF; Bare RL; Marshall MG; McCullough DL
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):83-8. PubMed ID: 10656377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between Day 0 dosimetric parameters and biochemical relapse-free survival in patients treated with transperineal permanent prostate interstitial brachytherapy with (125)I seeds.
    Garrán C; Ciérvide R; Cambeiro M; Moreno-Jiménez M; Ramos LI; Martínez-Monge R
    Brachytherapy; 2010; 9(1):8-14. PubMed ID: 19846350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
    Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.